Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Outcomes of Autologous Stem Cell Transplant in Primary and Secondary Central Nervous System Lymphoma - a Multi Center Experience in Singapore

Blood (2024) 144 (Supplement 1): 6467.

https://doi.org/10.1182/blood-2024-205120

Published: 2024

Journal Articles

Haploidentical Transplant Using Selective Ex-vivo TCR-Αβ Depleted and Upfront Memory T-Cell Add-Back Is Associated with Lower Chronic Gvhd and More Favorable Gvhd-Free/Relapse-Free Survival As Compared to Matched Related and Unrelated Donor Transplant for Adults with Hematological Malignancies

Blood (2024) 144 (Supplement 1): 3529.

https://doi.org/10.1182/blood-2024-200952

Published: 2024

Journal Articles

Outcome of Extra-Nodal Follicular Lymphoma Affected By Selection of Induction Chemoimmunotherapy and Maintenance Rituximab - Real-World Retrospective Study

Blood (2024) 144 (Supplement 1): 6277.

https://doi.org/10.1182/blood-2024-193417

Published: 2024

Journal Articles

Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial

Blood (2024) 144 (Supplement 1): 1765.

https://doi.org/10.1182/blood-2024-209537

Published: 2024

Journal Articles

The Endothelial Activation and Stress Index (EASIX) Score Improves Risk Stratification for Double Expressor Diffuse Large B-Cell Lymphoma (DEL)

Jing Yuan Tan, Jason Yongsheng Chan, Shin Yeu Ong, Chandramouli Nagarajan, Yunxin Chen, Francesca Lorraine Wei Inng Lim, Nicholas Francis Grigoropoulos, Ya Hwee Tan, Joshua Tian Ming Hoe, Jianbang Chiang, Esther Chang, Eileen Poon, Nagavalli Somasundaram, Miriam Tao, Yeow Tee Goh, Soon Thye Lim, Lawrence Cheng Kiat Ng

Blood (2024) 144 (Supplement 1): 6450.

https://doi.org/10.1182/blood-2024-194684

Published: 2024

Journal Articles

Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study

Jorge E. Cortes, Andreas Hochhaus, Timothy P Hughes, Jianxiang Wang, Dong-Wook Kim, Dennis Dong Hwan Kim, Jiri Mayer, Yeow Tee Goh, Philipp le Coutre, Gabriel Etienne, Naoto Takahashi, Inho Kim, David Andorsky, Ghayas C. Issa, Felice Bombaci, Shruti Kapoor, Rajendra Jinwal, Lillian Yau, Richard Larson

Blood (2024) 144 (Supplement 1): 475.

https://doi.org/10.1182/blood-2024-203757

Published: 2024

Journal Articles

Co-Expression of C-MYC/BCL2 Is Associated with Inferior Survival Outcomes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation - a Nationwide Retrospective Analysis in Singapore

Blood (2023) 142 (Supplement 1): 3601.

https://doi.org/10.1182/blood-2023-184423

Published: 2023

Journal Articles

Asciminib (ASC) in Combination with Imatinib (IMA), Nilotinib (NIL), or Dasatinib (DAS) May be a Potential Treatment (Tx) Option in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase or Accelerated Phase (Ph+ CML-CP/AP): Final Results from the Asciminib Phase 1 Study

Jorge Cortes, Fabian Lang, Delphine Rea, Andreas Hochhaus, Massimo Breccia, Yeow Tee Goh, Michael C. Heinrich, Timothy P Hughes, Jeroen J.W.M. Janssen, Philipp le Coutre, Hironobu Minami, Koji Sasaki, Daniel J. DeAngelo, Gessami Sanchez-Olle, Nathalie Pognan, Jomy Jose, Matthias Hoch, Michael Mauro

Blood (2023) 142 (Supplement 1): 868.

https://doi.org/10.1182/blood-2023-189270

Published: 2023

Journal Articles

Daratumumab Bortezomib and Dexamethasone in Transplant Ineligible Newly Diagnosed Elderly Myeloma Patients - a Trial By Asian Myeloma Network

Chandramouli Nagarajan, Melinda Tan, Yunxin Chen, Melissa Ooi, Sanjay De Mel, Allison Tso, Lawrence Ng, Hein Than, Yeow Tee Goh, Brian GM Durie, Wee-Joo Chng

Blood (2023) 142 (Supplement 1): 6721.

https://doi.org/10.1182/blood-2023-173476

Published: 2023

Journal Articles

Longitudinal Assessment of Transfusion Intensity in Patients with JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated with Momelotinib in the Phase 3 Simplify-1 and Momentum Trials

Ruben A. Mesa, Andrew C. Perkins, Yeow Tee Goh, Maria Laura Fox, Donal P McLornan, Jeanne Palmer, Lynda Foltz, Alessandro Maria Vannucchi, Steffen Koschmieder, Francesco Passamonti, Sung-Eun Lee, Jun Kawashima, Bryan Strouse, Francisco Gonzalez Carreras, Stephen T. Oh

Blood (2023) 142 (Supplement 1): 3182.

https://doi.org/10.1182/blood-2023-177774

Published: 2023

Journal Articles

With up to 8 Years of Therapy, Asciminib (ASC) Monotherapy Demonstrated Continued Favorable Efficacy, Safety, and Tolerability in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) without the T315I Mutation: Final Results from the Phase 1 X2101 Study

Blood (2023) 142 (Supplement 1): 450.

https://doi.org/10.1182/blood-2023-187322

Published: 2023

Journal Articles

Intensive Pegcetacoplan Dosing in the Management of Acute Hemolysis As Part of the 307 Open-Label Extension Study

Morag Griffin, Richard Kelly, Dries Deeren, Yeow Tee Goh, Eric Tse, Kensuke Usuki, Raymond Wong, Regina Horneff, Lisa Tan, Michael Yeh, Jessica Savage, Jeff Szer

Blood (2022) 140 (Supplement 1): 2937–2939.

https://doi.org/10.1182/blood-2022-163117

Published: 2022

Journal Articles

Daratumumab in Multiple Myeloma - a Nationwide Real-World Experience from Singapore

Allison Ching Yee Tso, Wee Joo Chng, Yeow Tee Goh, Melissa Ooi, Yunxin Chen, Chandramouli Nagarajan, Daryl Tan, Kiat Hoe Ong

Blood (2022) 140 (Supplement 1): 12596–12597.

https://doi.org/10.1182/blood-2022-157940

Published: 2022

Journal Articles

Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor

Blood (2022) 140 (Supplement 1): 1514–1517.

https://doi.org/10.1182/blood-2022-162783

Published: 2022

Journal Articles

Differential Activation of V γ 4V δ 1 and V γ 9V δ 2 Cord Blood Derived Gamma Delta T Cells upon Exposure to EBV-Lcl and K562 Cells

Jeremy Wee Kiat Ng, Joey Lai, Tony Kiat Hon Lim, William YK Hwang, Shang Li, Connie J. Eaves, Yeow Tee Goh, Alice Cheung

Blood (2021) 138 (Supplement 1): 2790.

https://doi.org/10.1182/blood-2021-152151

Published: 2021

Journal Articles

Efficacy and Safety of Pegcetacoplan Treatment in Complement-Inhibitor Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from the Phase 3 Prince Study

Raymond S Wong, Juan Ramon Navarro, Narcisa Sonia Comia, Yeow Tee Goh, Henry Idrobo, Daolada Kongkabpan, David Gomez-Almaguer, Mohammed Al-Adhami, Temitayo Ajayi, Paulo Alvarenga, Pascal Deschatelets, Cedric Francois, Federico Grossi, Teresita Dumagay

Blood (2021) 138 (Supplement 1): 606.

https://doi.org/10.1182/blood-2021-147493

Published: 2021

Journal Articles

Prognostic Value of Refined Disease Risk Index (rDRI) and Conditioning Regimen in Adult Patients Receiving Unrelated Cord Blood Transplantation (UCBT) for Haematological Malignancies - 15-Year Follow-up of Multicenter Study in Singapore

Qianhuang Ian Q Wu, MBBS, Yeh Ching Linn, MBBS, MRCP, William YK Hwang, MBBS, Michelle Poon, MBBS, MRCP, FRCPATH, Lip Kun Tan, MBBS, FRCP, FRCPath, Yang Liang Boo, MD, Yeow Tee Goh, MBBS, Aloysius YL Ho, MBBS,FRCP,FRCPath, Liang Piu Koh, MBBS, MRCP

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-141581

Published: 2020

Journal Articles

Phase I/II Dose-Escalation Study of Lenalidomide in Combination with R-GDP for Treatment of Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Followed By Maintenance Lenalidomide

Colin Phipps, MD, Chandramouli Nagarajan, MBBS, Lawrence Ng, MBBS, Jane L Chua, Yunxin Chen, MBBS, Shin Yeu Ong, MD, Melinda Si Yun Tan, MBBS, Nicholas Francis Grigoropoulos, MD PhD, Sathish Gopalakrishnan, MD, Heng Joo Ng, MBBS, William YK Hwang, MBBS, Yeow Tee Goh, MBBS, Yuh Shan Lee, MBBS

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-142275

Published: 2020

Journal Articles

The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes

Kim Huynh, BBiomedSc (Hons), PhD, Naomi Aoki, MSc, BSc, Kihyun Kim, MD PhD, Wee Joo Chng, MD PhD, Gin Gin Gan, MBBS, MRCP, FRCP, Chang-Ki Min, MD PhD, Je-Jung Lee, MD PhD, Yeow Tee Goh, MBBS, Cameron Wellard, Zoe McQuilten, MBBS, PhD, Elizabeth M. Moore, PhD, Erica M. Wood, MBBS, FRACP, FRCPA, Andrew Spencer, MBBS, FRACP, FRCPA, DM

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136896

Published: 2020

Journal Articles

Momelotinib's Spleen, Symptom and Anemia Efficacy Is Maintained in Intermediate/High Risk Myelofibrosis Patients with Thrombocytopenia

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-135880

Published: 2020

NARROW

Outcomes of Autologous Stem Cell Transplant in Primary and Secondary Central Nervous System Lymphoma - a Multi Center Experience in Singapore

Haploidentical Transplant Using Selective Ex-vivo TCR-Αβ Depleted and Upfront Memory T-Cell Add-Back Is Associated with Lower Chronic Gvhd and More Favorable Gvhd-Free/Relapse-Free Survival As Compared to Matched Related and Unrelated Donor Transplant for Adults with Hematological Malignancies

Outcome of Extra-Nodal Follicular Lymphoma Affected By Selection of Induction Chemoimmunotherapy and Maintenance Rituximab - Real-World Retrospective Study

Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial

The Endothelial Activation and Stress Index (EASIX) Score Improves Risk Stratification for Double Expressor Diffuse Large B-Cell Lymphoma (DEL)

Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study

Co-Expression of C-MYC/BCL2 Is Associated with Inferior Survival Outcomes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation - a Nationwide Retrospective Analysis in Singapore

Daratumumab Bortezomib and Dexamethasone in Transplant Ineligible Newly Diagnosed Elderly Myeloma Patients - a Trial By Asian Myeloma Network

Longitudinal Assessment of Transfusion Intensity in Patients with JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated with Momelotinib in the Phase 3 Simplify-1 and Momentum Trials

Intensive Pegcetacoplan Dosing in the Management of Acute Hemolysis As Part of the 307 Open-Label Extension Study

Daratumumab in Multiple Myeloma - a Nationwide Real-World Experience from Singapore

Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor

Differential Activation of V γ 4V δ 1 and V γ 9V δ 2 Cord Blood Derived Gamma Delta T Cells upon Exposure to EBV-Lcl and K562 Cells

Efficacy and Safety of Pegcetacoplan Treatment in Complement-Inhibitor Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from the Phase 3 Prince Study

Prognostic Value of Refined Disease Risk Index (rDRI) and Conditioning Regimen in Adult Patients Receiving Unrelated Cord Blood Transplantation (UCBT) for Haematological Malignancies - 15-Year Follow-up of Multicenter Study in Singapore

Phase I/II Dose-Escalation Study of Lenalidomide in Combination with R-GDP for Treatment of Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Followed By Maintenance Lenalidomide

The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes

Momelotinib's Spleen, Symptom and Anemia Efficacy Is Maintained in Intermediate/High Risk Myelofibrosis Patients with Thrombocytopenia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only